TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26903337

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Clinical recognition of ARDS
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Tidal volume management
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Plateau pressure measurement
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) management
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Hospital mortality rates
Number of subjects: 3022
Study: 26903408

Group type: EXPERIMENTAL
Intervention: Water (1l/d)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Dairy (skim milk, whey, casein)
Number of subjects: 173
Study: 26903522

Group type: EXPERIMENTAL
Intervention: All optic zone diffractive multifocal IOL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 50
Study: 26903524

Group type: EXPERIMENTAL
Intervention: INTRACOR treatment (Technolas femtosecond laser)
Number of subjects: 25
Study: 26903799

Group type: EXPERIMENTAL
Intervention: MAP variability parameters (ASV, CV, VIM) monitored at ICU
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: MAP variability parameters (CV, VIM) monitored at ICU
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Respiratory parameters (MIP, MEP, PEF)
Number of subjects: 44
Study: 26904207

Group type: EXPERIMENTAL
Intervention: Bronchodilator response (BDR)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Significant BDR
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Non-significant BDR
Number of subjects: 129
Study: 26904404

Group type: EXPERIMENTAL
Intervention: ASP2215 (novel FLT3-inhibitor)
Number of subjects: 0
Study: 26904570

Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m(2)/week and paclitaxel 50 mg/m(2)/week for 5 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cisplatin 40 mg/m(2)/week for 5 weeks (control arm)
Number of subjects: 81
Study: 26905333

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG-IUS)
Number of subjects: 75
Study: 26907184

Group type: EXPERIMENTAL
Intervention: Ertapenem (Empirical Therapy)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Other carbapenems (Empirical Therapy)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Ertapenem (Targeted Therapy)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Other carbapenems (Targeted Therapy)
Number of subjects: 704
Study: 26907630

Group type: EXPERIMENTAL
Intervention: CD19 CAR-T-cell therapy
Number of subjects: 7
Study: 26907745

Group type: EXPERIMENTAL
Intervention: CT esophagram
Number of subjects: 84
Study: 26908063

Group type: EXPERIMENTAL
Intervention: poly(ADP-ribose) polymerase inhibitors
Number of subjects: 0
Study: 26908089

Group type: EXPERIMENTAL
Intervention: Lurasidone (psychotropic medication)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 26908190

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26908408

Group type: EXPERIMENTAL
Intervention: Myocardial hemorrhage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Myocardial edema
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Infarct zone edema (T2, in ms)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic volume
Number of subjects: 30
Study: 26908541

Group type: EXPERIMENTAL
Intervention: Cost-efficient practices in large HIV trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New approaches to clinical trial infrastructure and financial management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central monitoring and harmonized regulations
Number of subjects: 0
Study: 26908748

Group type: EXPERIMENTAL
Intervention: Recent oral sex partners (within the prior 3 months) among men
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Lifetime vaginal sex partners among women
Number of subjects: 409

Group type: COMPARATOR
Intervention: Oral HPV infection clearance
Number of subjects: 409
Study: 26908756

Group type: EXPERIMENTAL
Intervention: FMP2.1/AS01 vaccine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Infectivity control
Number of subjects: 15
Study: 26908786

Group type: EXPERIMENTAL
Intervention: r-hIL-7 (20 µg/kg)
Number of subjects: 107
Study: 26908804

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF on all samples
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF on standard samples
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF on alternative samples
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF on nasopharyngeal aspirate and stool
Number of subjects: 281
Study: 26908855

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 394
Study: 26911200

Group type: EXPERIMENTAL
Intervention: Extended CRT (54Gy and 6 cycles of 5FU-based chemotherapy)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard CRT (54Gy and 2 cycles of 5FU-based chemotherapy)
Number of subjects: 111
Study: 26911310

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 53
Study: 26911408

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus panitumumab (5-FU, 3,200 mg/m(2), 48-hour continuous intravenous infusion; leucovorin, 200 mg/m(2) i.v.; irinotecan, 125 mg/m(2); oxaliplatin, 85 mg/m(2) i.v.; panitumumab, 6 mg/kg i.v.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus panitumumab
Number of subjects: 15
Study: 26911477

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy and other tyrosine kinase inhibitors (erlotinib, afatinib)
Number of subjects: 0
Study: 26911519

Group type: COMPARATOR
Intervention: Late spring/early summer period (April to June)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Treg numbers and function
Number of subjects: 26
Study: 26911583

Group type: EXPERIMENTAL
Intervention: NT-proBNP level assessment
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: High (>2370 ng/L) and intermediate (806-2370 ng/L) NT-proBNP levels
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Intermediate or high NT-proBNP level
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Intermediate or high NT-proBNP level, presence of dementia, higher ASA classification
Number of subjects: 182
Study: 26911589

Group type: EXPERIMENTAL
Intervention: Meeting MVPA guidelines
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: MVPA and longer sleep duration
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Screen time (ST) and healthy diet score
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Unhealthy diet score
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Interactions between lifestyle behaviours
Number of subjects: 374
Study: 26911812

Group type: EXPERIMENTAL
Intervention: Uninsured patients
Number of subjects: 279654

Group type: COMPARATOR
Intervention: Factors associated with being uninsured (vs Medicaid-insured)
Number of subjects: 279654
Study: 26911864

Group type: EXPERIMENTAL
Intervention: qPCR defined abnormal vaginal microbiota
Number of subjects: 130

Group type: COMPARATOR
Intervention: Nugent-defined BV
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Overall clinical pregnancy rate
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: qPCR diagnostic approach
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Nugent intermediate flora
Number of subjects: 130
Study: 26912134

Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg bd in combination with Cisplatin (25 mg/m²) and Gemcitabine (1000 mg/m²) administered on days 1 and 8 of a 21-day cycle.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cisplatin and Gemcitabine (CisGem) standard of care.
Number of subjects: 13
Study: 26912444

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Antiandrogens
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: (223)Ra-dichloride
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MATV response
Number of subjects: 42
Study: 26912485

Group type: EXPERIMENTAL
Intervention: Social skills group training ('KONTAKT')
Number of subjects: 22
Study: 26912492

Group type: EXPERIMENTAL
Intervention: High-normal VitB12 concentration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-normal VitB12 concentration
Number of subjects: 100
Study: 26913587

Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Higher side effect expectations
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Negative necessity-concern balance
Number of subjects: 166
Study: 26913693

Group type: EXPERIMENTAL
Intervention: Repeat bone marrow aspiration after induction therapy
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Delay in bone marrow aspiration (≥7 days)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: MRD-positive at original aspiration vs MRD-negative at repeat aspiration
Number of subjects: 289
Study: 26913697

Group type: EXPERIMENTAL
Intervention: Bendamustine + rituximab (BR) induction
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Maintenance lenalidomide (5-10 mg/d for 12 cycles)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Bendamustine + rituximab (BR) induction without maintenance therapy
Number of subjects: 34
Study: 26913756

Group type: EXPERIMENTAL
Intervention: Disaccharidase activity (lactase, sucrase, maltase, palatinase)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin and lactoferrin levels
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intestinal permeability (rhamnose/lactulose test)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Mucosal inflammation on intestinal biopsy
Number of subjects: 61
Study: 26915009

Group type: EXPERIMENTAL
Intervention: Autologous Protein Solution (APS)
Number of subjects: 11
Study: 26915641

Group type: EXPERIMENTAL
Intervention: Individualized and family-based lifestyle intervention
Number of subjects: 506

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 506
Study: 26915709

Group type: EXPERIMENTAL
Intervention: Tight control
Number of subjects: 987

Group type: COMPARATOR
Intervention: Less tight control
Number of subjects: 987
Study: 26916450

Group type: COMPARATOR
Intervention: Primary care
Number of subjects: 17374

Group type: COMPARATOR
Intervention: Specialist care
Number of subjects: 17374
Study: 26916481

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation
Number of subjects: 1305

Group type: COMPARATOR
Intervention: BVS-specific implantation strategy
Number of subjects: 1305
Study: 26916565

Group type: EXPERIMENTAL
Intervention: In-patient rehabilitation after NPM SAH
Number of subjects: 66

Group type: COMPARATOR
Intervention: NPM SAH without rehabilitation
Number of subjects: 66
Study: 26916582

Group type: EXPERIMENTAL
Intervention: Toe-brachial index (TBI) measurement in men
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Toe-brachial index (TBI) measurement in women
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI) measurement
Number of subjects: 73

Group type: COMPARATOR
Intervention: Comparison of TBI with published reference values
Number of subjects: 73

Group type: COMPARATOR
Intervention: Gender comparison of TBI
Number of subjects: 73

Group type: COMPARATOR
Intervention: Variability of TBI in women
Number of subjects: 73
Study: 26916841

Group type: EXPERIMENTAL
Intervention: Family-based intervention strategies for adolescent HIV prevention including family meetings, communal parenting, and building efficacy around parent-adolescent communication.
Number of subjects: 82
Study: 26917438

Group type: EXPERIMENTAL
Intervention: Mechanical debridement and systemic antibiotics
Number of subjects: 60
Study: 26917486

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel/Depot
Number of subjects: 273
Study: 26917615

Group type: EXPERIMENTAL
Intervention: Discontinued anticoagulation after negative D-dimer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remained without anticoagulation despite positive D-dimer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New isolated PE recurrences
Number of subjects: 0
Study: 26917617

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 0
Study: 26918032

Group type: EXPERIMENTAL
Intervention: Foreign-born blacks (FBB)
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1035
Study: 26918124

Group type: EXPERIMENTAL
Intervention: Oral antithrombotic drugs
Number of subjects: 4700000
Study: 26918192

Group type: EXPERIMENTAL
Intervention: Visceral fat measurement via dual-energy X-ray absorptiometry
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Supine forced expiratory volume in 1 s
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sniff maximum pressure
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Mean overnight arterial oxygen saturation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ventilatory response to 15% O2 breathing
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 71
Study: 26919263

Group type: EXPERIMENTAL
Intervention: Single-operator choledochoscopy (SOC) during ERCP
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Post-procedure intravenous antibiotic administration
Number of subjects: 72
Study: 26919403

Group type: EXPERIMENTAL
Intervention: Continuous ADT
Number of subjects: 180

Group type: COMPARATOR
Intervention: Intermittent ADT
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PCA3 score < level of quantification
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Baseline metastatic disease
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Testosterone level
Number of subjects: 180
Study: 26919994

Group type: EXPERIMENTAL
Intervention: Lower limb muscle strength (LMS)
Number of subjects: 345
Study: 26920463

Group type: EXPERIMENTAL
Intervention: Epicutaneous immunotherapy using the Viaskin patch, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26920495

Group type: EXPERIMENTAL
Intervention: Gait speed <0.5 m/s (slowest walkers)
Number of subjects: 8039

Group type: EXPERIMENTAL
Intervention: Gait speed 0.5-0.83 m/s (slow walkers)
Number of subjects: 8039

Group type: EXPERIMENTAL
Intervention: Gait speed >0.83 m/s (normal walkers)
Number of subjects: 8039

Group type: EXPERIMENTAL
Intervention: Each 0.2 m/s decrease in gait speed
Number of subjects: 8039

Group type: COMPARATOR
Intervention: Slowest walkers compared to normal walkers
Number of subjects: 8039
Study: 26920668

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 142
Study: 26920728

Group type: EXPERIMENTAL
Intervention: ABC stroke risk score
Number of subjects: 15701

Group type: COMPARATOR
Intervention: CHA2DS2-VASc score
Number of subjects: 15701
Study: 26920731

Group type: EXPERIMENTAL
Intervention: Serum trans fatty acids (TFAs)
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Serum trans 16:1n7
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Serum trans 18:1
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Trans 16:1n7 and trans 18:1
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Plasma ADMA levels
Number of subjects: 1364
Study: 26921148

Group type: EXPERIMENTAL
Intervention: New prediction model for 60-day hospital mortality
Number of subjects: 3746

Group type: EXPERIMENTAL
Intervention: New prediction model for 60-day ICU mortality
Number of subjects: 3746

Group type: COMPARATOR
Intervention: APACHE II score alone
Number of subjects: 3746
Study: 26921281

Group type: EXPERIMENTAL
Intervention: JetStream XC atherectomy device
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Adjunctive balloon angioplasty
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Embolic filter protection
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Non-procedure-related adverse events
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Postatherectomy stent integrity
Number of subjects: 29
Study: 26921283

Group type: EXPERIMENTAL
Intervention: Parental supply of sips of alcohol
Number of subjects: 1729
Study: 26922148

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (increased quantities of energy, protein, fat, essential fatty acids and vitamin A), n=24
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (standard nutrition), n=22
Number of subjects: 46
Study: 26922278

Group type: EXPERIMENTAL
Intervention: Standard education
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: No education
Number of subjects: 71

Group type: COMPARATOR
Intervention: Candidates for LVAD treatment
Number of subjects: 71
Study: 26922498

Group type: EXPERIMENTAL
Intervention: NOWAPI(®)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Polygraphy
Number of subjects: 22
Study: 26923436

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) 400 mg/day with median starting ribavirin (RBV) dose of 800 mg (IQR: 400-1200)
Number of subjects: 1789

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) 400 mg/day
Number of subjects: 1789

Group type: EXPERIMENTAL
Intervention: RBV-free regimens
Number of subjects: 1789
Study: 26923627

Group type: EXPERIMENTAL
Intervention: Highest ODI tertile (severe OSA)
Number of subjects: 302

Group type: COMPARATOR
Intervention: First ODI tertile (mild OSA)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Second ODI tertile (moderate OSA)
Number of subjects: 302
Study: 26923772

Group type: EXPERIMENTAL
Intervention: Vimentin-positive CTCs
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Ki67-positive CTCs
Number of subjects: 93
Study: 26923925

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) delivered by bachelor-level lay providers (BLPs)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) delivered by PhD-level expert providers (PLPs)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study: 26924501

Group type: EXPERIMENTAL
Intervention: (18)F-FDS
Number of subjects: 0
Study: 26924633

Group type: EXPERIMENTAL
Intervention: Bipolar disorder (BD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 39
Study: 26924680

Group type: EXPERIMENTAL
Intervention: DDC gene common genetic polymorphisms (haplotypes)
Number of subjects: 120
Study: 26925252

Group type: EXPERIMENTAL
Intervention: ADA discontinuation
Number of subjects: 220

Group type: COMPARATOR
Intervention: ADA continuation
Number of subjects: 220
Study: 26926297

Group type: EXPERIMENTAL
Intervention: Urinary indices of GAG fragmentation in septic shock patients
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Urinary indices of GAG fragmentation using dimethylmethylene blue assay in septic shock patients
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Urinary indices of GAG fragmentation in ARDS patients
Number of subjects: 125

Group type: COMPARATOR
Intervention: Nonseptic ICU control (surgical ICU patients)
Number of subjects: 125
Study: 26926629

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 123
Study: 26926644

Group type: EXPERIMENTAL
Intervention: Clindamycin intravenous dosing regimens (5 mg/kg for ≤32 weeks PMA, 7 mg/kg for 32 to 40 weeks PMA, 9 mg/kg for >40 to 60 weeks PMA) administered every 8 hours
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 62
Study: 26926676

Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone in patients with RS ≤ 11
Number of subjects: 3198

Group type: COMPARATOR
Intervention: Chemotherapy in patients with RS > 25
Number of subjects: 3198

Group type: COMPARATOR
Intervention: Chemotherapy in patients with RS 12 to 25
Number of subjects: 3198
Study: 26927285

Group type: EXPERIMENTAL
Intervention: Furosemide-based diuretic regimen
Number of subjects: 3
Study: 26927672

Group type: EXPERIMENTAL
Intervention: Octanoic acid (OA) administered in doses ranging from 8 to 128 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Octanoic acid (OA)
Number of subjects: 0
Study: 26928166

Group type: EXPERIMENTAL
Intervention: Anaesthesia practice (specific intervention details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study: 26928328

Group type: EXPERIMENTAL
Intervention: VTX-2337
Number of subjects: 13
Study: 26929095

Group type: EXPERIMENTAL
Intervention: MyPlan 1.0 (GPs' intervention group)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: MyPlan 1.0 (researchers' intervention group)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Usual care (waiting-list control group)
Number of subjects: 426
Study: 26929286

Group type: EXPERIMENTAL
Intervention: Amended classification system for open abdomen
Number of subjects: 542
Study: 26929418

Group type: EXPERIMENTAL
Intervention: Shorter regimen using currently available TB drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bedaquiline-containing regimens (all-oral and shortened version)
Number of subjects: 0

Group type: COMPARATOR
Intervention: WHO-recommended standard of care
Number of subjects: 0
Study: 26929648

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg IV every 14 days) and Erlotinib (150 mg oral daily)
Number of subjects: 44
Study: 26929777

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26930146

Group type: EXPERIMENTAL
Intervention: HPV4 vaccine (1-3 doses)
Number of subjects: 2091
Study: 26930208

Group type: EXPERIMENTAL
Intervention: Pneumovax (PPV23) immunization
Number of subjects: 0
Study: 26930527

Group type: EXPERIMENTAL
Intervention: Omega-3 arm (930 mg EPA/750 mg DHA + 50 mg/d sertraline)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sertraline plus placebo arm
Number of subjects: 122
Study: 26930627

Group type: EXPERIMENTAL
Intervention: Favipiravir (day 0: 6,000 mg; day 1 to day 9: 2,400 mg/d)
Number of subjects: 126
Study: 26930634

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) patients
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Higher apnea-hypopnea index (AHI)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Higher levels of PlGF
Number of subjects: 538

Group type: COMPARATOR
Intervention: Control group (non-OSA patients)
Number of subjects: 538
Study: 26931117

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 1109